The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)
| Autor: | Jun Wada, Motofumi Sasaki, Chikage Sato Horiguchi, Yoshio Nakamura, Kazutoshi Murakami, Haruhito A. Uchida, Hirofumi Makino, Tomoko Miyoshi, Daisuke Ogawa |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Subcutaneous Fat Tetrazoles Adipose tissue Blood Pressure Intra-Abdominal Fat Essential hypertension Benzoates Body Mass Index Insulin resistance Diabetes mellitus Internal medicine Internal Medicine Humans Medicine Telmisartan Aged Metabolic Syndrome business.industry Body Weight Valine Middle Aged medicine.disease PPAR gamma Treatment Outcome Endocrinology Valsartan Hypertension Benzimidazoles Female Insulin Resistance Waist Circumference Metabolic syndrome Tomography X-Ray Computed Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers Body mass index medicine.drug |
| Zdroj: | Diabetes and Vascular Disease Research. 10:93-96 |
| ISSN: | 1752-8984 1479-1641 |
| DOI: | 10.1177/1479164112444640 |
| Popis: | Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm2 in the TELMI group ( p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm2, the change was not significant ( p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|